Form POS AM - Post-Effective amendments for registration statement:
SEC Accession No. 0001213900-25-099986
Filing Date
2025-10-17
Accepted
2025-10-17 16:38:02
Documents
54

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea0226019-17.htm   iXBRL POS AM 5090391
2 CONSENT OF MARCUM LLP ea022601917ex23-2_nlspharma.htm EX-23.2 1648
3 CONSENT OF KOST FORRER GABBAY & KASIERER, A MEMBER OF ERNST & YOUNG GLOBAL ea022601917ex23-4_nlspharma.htm EX-23.4 5670
9 GRAPHIC ex23-4_001.jpg GRAPHIC 7177
10 GRAPHIC tnls_logo.jpg GRAPHIC 56406
  Complete submission text file 0001213900-25-099986.txt   9856544

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nlsp-20250630.xsd EX-101.SCH 44189
5 XBRL CALCULATION FILE nlsp-20250630_cal.xml EX-101.CAL 29387
6 XBRL DEFINITION FILE nlsp-20250630_def.xml EX-101.DEF 216100
7 XBRL LABEL FILE nlsp-20250630_lab.xml EX-101.LAB 413473
8 XBRL PRESENTATION FILE nlsp-20250630_pre.xml EX-101.PRE 234110
58 EXTRACTED XBRL INSTANCE DOCUMENT ea0226019-17_htm.xml XML 841867
Mailing Address THE CIRCLE 6 8058 ZURICH Switzerland
Business Address THE CIRCLE 6 8058 ZURICH Switzerland 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: POS AM | Act: 33 | File No.: 333-284075 | Film No.: 251401253
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)